Cardiology Division, S. Maria della Stella Hospital, Orvieto.
Clinica Salus Infirmorum, S. Filippo Neri Hospital, Rome.
J Cardiovasc Med (Hagerstown). 2024 Jul 1;25(7):551-558. doi: 10.2459/JCM.0000000000001641. Epub 2024 May 28.
In patients undergoing pacemaker implantation with no prior history of heart failure (HF), the presence of left bundle branch block (LBBB) has been identified as an independent predictor of HF-related death or hospitalization, while the prognostic significance of right bundle branch block (RBBB) remains uncertain. We aimed to assess the long-term risk of all-cause mortality in patients with a standard indication for permanent pacing and normal or moderately depressed left ventricular function when RBBB is detected at the time of implantation.
We retrospectively enrolled 1348 consecutive patients who had undergone single- or dual-chamber pacemaker implantation at the study center, from January 1990 to December 2022. Patients with a left ventricular ejection fraction ≤35% or a prior diagnosis of HF were excluded.
The baseline 12-lead electrocardiogram revealed an RBBB in 241 (18%) and an LBBB in 98 (7%) patients. During a median follow-up of 65 [25th-75th percentile: 32-117] months, 704 (52%) patients died. The combined endpoint of cardiovascular death or HF hospitalization was reached by 173 (13%) patients. On multivariate analysis, RBBB was confirmed as an independent predictor of death [hazard ratio, 1.33; 95% confidence interval (CI), 1.09-1.63; P = 0.005]. However, when considering the combined endpoint of cardiovascular death and HF hospitalization, this endpoint was independently associated with LBBB (hazard ratio, 2.13; 95% CI, 1.38-3.29; P < 0.001), but not with RBBB.
In patients with standard pacemaker indications and normal or moderately depressed left ventricular function, the presence of basal RBBB was an independent predictor of mortality. However, it was not associated with the combined endpoint of cardiovascular death and HF hospitalization.
在无心力衰竭(HF)既往史的接受起搏器植入的患者中,左束支传导阻滞(LBBB)的存在已被确定为 HF 相关死亡或住院的独立预测因素,而右束支传导阻滞(RBBB)的预后意义尚不确定。我们旨在评估在植入时检测到 RBBB 且具有标准永久性起搏适应证和正常或中度左心室功能的患者的全因死亡率的长期风险。
我们回顾性纳入了自 1990 年 1 月至 2022 年 12 月在研究中心接受单腔或双腔起搏器植入的 1348 例连续患者。排除左心室射血分数≤35%或有 HF 既往诊断的患者。
基线 12 导联心电图显示 241 例(18%)患者存在 RBBB,98 例(7%)患者存在 LBBB。在中位随访 65[25 至 75 分位:32 至 117]个月期间,704 例(52%)患者死亡。173 例(13%)患者达到心血管死亡或 HF 住院的联合终点。多变量分析证实 RBBB 是死亡的独立预测因素[风险比,1.33;95%置信区间(CI),1.09-1.63;P=0.005]。然而,当考虑心血管死亡和 HF 住院的联合终点时,该终点与 LBBB 独立相关(风险比,2.13;95%CI,1.38-3.29;P<0.001),但与 RBBB 无关。
在具有标准起搏器适应证和正常或中度左心室功能的患者中,基础 RBBB 的存在是死亡率的独立预测因素。然而,它与心血管死亡和 HF 住院的联合终点无关。